EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure

Jean-Claude Tardif, Jean Rouleau, Glenn M Chertow, Ayman Al-Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S Desai, Alexander Chernyavskiy, Maria Evsina, Béla Merkely und 2 weitere

ESC Heart Failure · 01.04.2023 · 10 (2) · 1066-1076

DOI: 10.1002/ehf2.14268 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 23.12.2022. Verfasst von Jean-Claude Tardif und 13 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Heart Institute, Université de Montréal, 5000 Belanger Street East, Montreal, H1T1C8, Quebec, Canada. Hauptthemen laut MEDLINE: Heart Failure, COVID-19. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is an orally administered non-absorbed intestinal potassium binder proven to lower serum potassium concentrations. Methods and results PRIORITIZE-HF was an international, multicentre, parallel-group, randomized, double-blind, placebo-controlled study to evaluate the benefits and risks of using SZC to intensify RAAS inhibitor therapy. Patients with symptomatic HFrEF were eligible and randomly assigned to receive SZC 5 g or placebo once daily for 12 weeks. Doses of study medication and RAAS inhibitors were titrated during the treatment period. The primary endpoint was the proportion of patients at 12 weeks in the following categories: (i) any RAAS inhibitor at less than target dose, and no MRA; (ii) any RAAS inhibitor at target dose and no MRA; (ii) MRA at less than target dose; and (iv) MRA at target dose. Due to challenges in participant management related to the COVID-19 pandemic, the study was prematurely terminated with 182 randomized patients. There was no statistically significant difference in the distribution of patients by RAAS inhibitor treatment categories at 3 months (P = 0.43). The proportion of patients at target MRA dose was numerically higher in the SZC group (56.4%) compared with the placebo group (47.0%). Overall, SZC was well tolerated.

Conclusions

PRIORITIZE-HF was terminated prematurely due to COVID-19 and did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with the potassium-reducing agent SZC compared with placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCOVID-19HumansPandemicsStroke VolumePotassiumAldosteroneSilicates

Stichwörter der Autor:innen

Guideline-directed medical therapyHeart failure with reduced ejection fractionHyperkalaemiaRAAS inhibitorsSodium zirconium cyclosilicate

Substanzen

PotassiumAldosteronesodium zirconium cyclosilicateSilicates

Autor:innen und Institutionen

  • Montreal Heart Institute, Université de Montréal, 5000 Belanger Street East, Montreal, H1T1C8, Quebec, Canada.
  • Stanford University School of Medicine, Palo Alto, CA, USA.
  • AstraZeneca, Stockholm, Sweden.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • E. Meshalkin National Medical Research Center, Ministry of Health of the Russia Federation, Moscow, Russia.
  • Aramil City Hospital, Aramil, Russia.

Förderung

  • AstraZeneca

Zitieren

APA

Tardif, J. C., Rouleau, J., Chertow, G. M., Al-Shurbaji, A., Lisovskaja, V., Gustavson, S., Zhao, Y., Bouabdallaoui, N., Desai, A. S., Chernyavskiy, A., Evsina, M., Merkely, B., McMurray, J. J. V., & Pfeffer, M. A. (2023). Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure. ESC Heart Failure, 10(2), 1066-1076. https://doi.org/10.1002/ehf2.14268

Vancouver

Tardif JC, Rouleau J, Chertow GM, Al-Shurbaji A, Lisovskaja V, Gustavson S, et al. Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure. ESC Heart Failure. 2023;10(2):1066-1076. doi:10.1002/ehf2.14268

BibTeX
@article{Tardif2023,
  author = {Tardif, Jean-Claude and Rouleau, Jean and Chertow, Glenn M and Al-Shurbaji, Ayman and Lisovskaja, Vera and Gustavson, Stephanie and Zhao, Yanli and Bouabdallaoui, Nadia and Desai, Akshay S and Chernyavskiy, Alexander and Evsina, Maria and Merkely, Béla and McMurray, John J V and Pfeffer, Marc A},
  title = {Potassium Reduction with Sodium Zirconium Cyclosilicate in Patients with Heart Failure},
  journal = {ESC Heart Failure},
  year = {2023},
  volume = {10},
  number = {2},
  pages = {1066--1076},
  doi = {10.1002/ehf2.14268}
}
Kostenlos starten →